Strategy Articles - Pharmaceutical Executive

ADVERTISEMENT

Strategy Articles
The art and science of running a successful pharmaceutical company.

Drug Safety: Failure to Communicate

September 1, 2007

Many see Vioxx and Avandia as clear signs that the drug safety system has failed. As soon as reports of these drugs' adverse events began to flood the media, consumers—and Congress—demanded to know: "Why didn't we know sooner?"

Safety Net

July 30, 2007

A new class of scales that can help capture drug effects—not necessarily disease impacts, as quality-of-life instruments currently do—will likely be needed to identify the meaning of the drug's benefits to patients

Avandia Sales Away

July 30, 2007

Avandia's market share erosion was magnified further by the almost complete absence of new prescriptions being switched to Avandia from its competitors. In the weeks before the event, Avandia accounted for more than 20 percent of all switches by primary care physicians

Tibotec Gets AIDS

July 30, 2007

Tibotec is set to launch a second revolution in HIV treatment—­and make a run at Glaxo, BMS, and Abbott, the longtime market kingpins

Harbingers of Change

July 3, 2007

As generics manufacturers grow more aggressive, will branded companies follow suit by deploying thorough patent strategies—and crack legal teams? Will government efforts in Japan finally bring cancer out of the shadows and spur oncology sales? Will the adoption of intellectual property rights drive pharma growth in India and help push the country to the top tier of global economic powers? These questions point to developments—some of them flying beneath the radar—that we expect to have major implications for pharmaceutical companies down the road. Each year, IMS identifies the key events that it believes will have a significant impact on the global pharmaceutical market. Here, we reveal those events—the harbingers of change—that will define and reshape the market through 2007 and for years to come.

Culture Shock

July 3, 2007

What's old and established is in, what's new—and once interpreted as"better"—is out

Take Me to Your Leader

July 3, 2007

It's bittersweet being one of the leaders of an industry that is not sustainable," a top pharma CEO recently told Carolyn Buck Luce, Ernst & Young's global pharmaceutical sector leader. Bittersweet is a poignant word for a hard-driving exec to issue.

A Very Specialty Moment

June 1, 2007

While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.

Consumerization: Pandora's Pillbox

June 1, 2007

To harness consumerization to improve the industry's image and enhance the value of its products, pharma leaders need to focus on the "Four Cs": commitment, choice, collaboration, and customization

ADVERTISEMENT

Click here